证券代码：300642 证券简称：透景生命 | --- | --- | |------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2021002 | --- | --- | --- | --- | --- | |------------------------------------------|---------|----------------------------------------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | | | | | | 特定对象调研 | | □媒体采访 □分析师会议 | | 投资者关系 活动类别 | | □新闻发布会 □业绩说明会 | ...

证券代码：300642 证券简称：透景生命 | --- | |-------| | | | | | | | | | | | | | | | | | | | | | | | | 安信证券马帅、李奔，金元顺安基金贾丽杰，盛世知己王小刚，臻禾投资张栋， 中欧基金王建礼 时 间 2021 年 02 月 04 日 地 点 上海市浦东新区碧波路 572 弄 115 号 1 幢公司会议室 | --- | --- | --- | |--------------|--------------------|-------| | | | | | 上市公司 | | | | 接待人员姓名 | 董事会秘书：王小清 | | 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2021001 | --- | --- | --- | --- | --- | --- | --- | |----------------------|-------------|---------|------------------------------------|-------|-------|-------| | | | | | | | | | ...

Group 1: Marketing Reform and Growth - The company completed a marketing organizational restructuring by the end of 2020, increasing the marketing staff from 80 to approximately 140 people, with plans for further expansion in 2021 [1] - The immune and molecular product lines have maintained stable and rapid growth, achieving a strong market position [1] Group 2: Product Development and Market Strategy - The company aims to leverage the in vitro diagnostic industry and domestic substitution policies to gain a larger market share [3] - The flow cytometry technology used for autoimmune detection products offers advantages such as rapid joint testing, full automation, and digital results, expected to become a significant product in the next 3 to 5 years [3] - The company plans to increase the installation of flow cytometry and chemiluminescence instruments to ensure stable reagent revenue [3] Group 3: Revenue and Product Lines - The revenue from tumor markers is expected to grow steadily due to the results of marketing reforms and the stable output of previously deployed instruments [3] - The company’s molecular products include HPV nucleic acid detection, companion diagnostics, and cancer detection products, with HPV being a key focus [5] - The company plans to introduce cartridge-based PCR detection products, which will overcome laboratory space and personnel limitations, potentially becoming an important technology platform for future molecular detection [5]

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2021004 | --- | --- | --- | --- | --- | --- | |-------------------------|-------|-----------------------------------------------------------|-------------------------|------------------------------------------------------------------------------|------------------------------------------------------------------------------------| | 投资者关系 活动类别 | | 特定对象调研 □媒体采访 \n□新闻发布会 \n□现场参观 | \n \n□其他： | 业绩说明会 □路演活动 | □分析师会议 | | 参与单位名称 及人员姓名 | | 通过全景网"投资者关系互动平台"（ 度网上业绩 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2021006 | --- | --- | --- | --- | --- | |------------------------------------------|-------|--------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------------------------------| | 投资者关系 活动类别 | | 特定对象调研 \n□新闻发布会 □业绩说明会 \n□现场参观 □其他： | □媒体采访 □分析师会议 \n \n | □路演活动 | | 参与单位名称 及人员姓名（排 名不分先后） | | | 国海证券许睿、朱凤萍，华安证券黎一江、方晨、王雨晴 | | | 时 间 | ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2022004 | --- | --- | --- | --- | --- | |------------------------------------------|-------|---------------------------|------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系 活动类别 | | □新闻发布会 \n□现场参观 | □特定对象调研 □媒体采访 □分析师会议 \n | □业绩说明会 □路演活动 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 2021 年度业绩说明会 投资者活动记录表 编号：IR-2022003 | --- | --- | --- | --- | |-------------------|--------------------------------------------------------------------------------|--------------------------------------------------|-------------------------------| | | | | | | | □特定对象调研 □分析师会议 | | | | | □媒体采访 | 业绩说明会 | | | 投资者关系活动类 | □新闻发布会 □路演活动 | | | | 别 | □现场参观 □电话会议 | | | | | □其他：（请文字说明其他活动内容） | | | | 参与单位名称 | 透景生命 2021 年度业绩说明会采用网络远程方式进行，面向全体投资者 | | | | 及人员姓名 | | | | | 时间 | 2022 年 5 月 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2022006 | --- | --- | --- | --- | |-------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------------------------| | 投资者关系 活动类别 | □新闻发布会 \n 现场参观 | □特定对象调研 □媒体采访 □分析师会议 \n□业绩说明会 □路演活动 \n□其他： | | | | | | 国金证券赵骁翔、汝吉瑞、开源证券岑峻宇、湘财证券陈澈、德邦证券韩力 | | | | | 嵬、招商证券黄力源、中 ...

证券代码：300642 证券简称：透景生命 上海透景生命科技股份有限公司 投资者关系活动记录表 编号：IR-2022005 | --- | --- | --- | --- | --- | |------------------------------------------|-------|----------------------------------------------------------------------|----------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | | | | ...